Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Breast Cancer Research

Fig. 5

From: A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Fig. 5

Expression of cdc7 and RNAII (POLR2A) is linked to poor prognosis in breast cancer patients. Metastasis-free survival curves illustrating the relationship between expression of cdc7 or RNAII (POLR2A) and prognosis in ER-negative breast cancer patients. Curves derived from gene expression and available survival data for 123 lymph node-negative, non-neoadjuvantly treated, ER-negative breast cancer patients at Erasmus MC Rotterdam. N = the number of patients in the group. F = the number of patients who relapsed (distant metastasis)

Back to article page